Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
- DOI
- 10.1016/s1470-2045(17)30690-3
- Published
- 2017 Dec
- Container
- The Lancet. Oncology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s1470-2045-17-30690-3,
title = {Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.},
author = {Brahmer JR and Rodríguez-Abreu D and Robinson AG and Hui R and Csőszi T and Fülöp A and Gottfried M and Peled N and Tafreshi A and Cuffe S and O'Brien M and Rao S and Hotta K and Zhang J and Lubiniecki GM and Deitz AC and Rangwala R and Reck M},
year = {2017},
journal = {The Lancet. Oncology},
doi = {10.1016/s1470-2045(17)30690-3},
url = {https://doi.org/10.1016/s1470-2045(17)30690-3}
}RIS
TY - JOUR TI - Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. AU - Brahmer JR AU - Rodríguez-Abreu D AU - Robinson AG AU - Hui R AU - Csőszi T AU - Fülöp A AU - Gottfried M AU - Peled N AU - Tafreshi A AU - Cuffe S AU - O'Brien M AU - Rao S AU - Hotta K AU - Zhang J AU - Lubiniecki GM AU - Deitz AC AU - Rangwala R AU - Reck M PY - 2017 JO - The Lancet. Oncology DO - 10.1016/s1470-2045(17)30690-3 UR - https://doi.org/10.1016/s1470-2045(17)30690-3 ER -
APA
JR, B., D, R., AG, R., R, H., T, C., A, F., M, G., N, P., A, T., S, C., M, O., S, R., K, H., J, Z., GM, L., AC, D., R, R., & M, R. (2017). Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(17)30690-3
Source records
- pubmed · retrieved 2026-09-27T14:35:56.749Z